Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5018987 | 0.98 | USP2 (0.71) | USP2POLBALDH1A1GAAMEN1 | |
| SCHEMBL22217089 | 0.96 | USP2 (0.62) | USP2POLBALDH1A1GAAMEN1 | |
| SCHEMBL27406555 | 0.86 | USP2 (0.63) | USP2POLBALDH1A1GAAMEN1 | |
| SCHEMBL25470810 | 0.84 | USP2 (0.57) | USP2POLBALDH1A1MEN1KMT2A | |
| SCHEMBL27532497 | 0.84 | USP2 (0.67) | USP2POLBALDH1A1GAAMEN1 | |
| SCHEMBL25081110 | 0.84 | SMN1; SMN2 (0.76) | USP2POLBMEN1KMT2ATSHR | |
| SCHEMBL400508 | 0.84 | POLB (0.67) | USP2POLBALDH1A1GAAMEN1 | |
| SCHEMBL7024566 | 0.82 | MEN1 (0.69) | POLBALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3568101 | 0.81 | USP2 (0.68) | USP2POLBALDH1A1GAAMEN1 | |
| SCHEMBL6302757 | 0.81 | USP2 (0.68) | USP2POLBALDH1A1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558981-B1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-20200299280-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-10717726-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2020-07-21 | — | — | US | disclosed |
| US-20110312945-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110312945-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110312945-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
| US-7825160-B2 | such as [5-(4-Fluoro-benzyloxy)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, used for the treatment of Alzheimer's disease and for the modulation of gamma -secretase activity | CELLZOME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| WO-2010039982-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20090118289-A1 | (Biphenyl) Carboxylic Acids and Derivatives Thereof | CELLZOME AG (DE) | 2009-05-07 | — | — | US | disclosed |
| EP-1805129-B1 | (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | CELLZOME LTD (GB) | 2009-03-18 | — | — | EP | disclosed |
| US-7253158-B2 | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1805129-A1 | (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | CELLZOME AG (DE) | 2007-07-11 | — | — | EP | disclosed |
| EP-1768960-A1 | SULFONAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006045554-A1 | (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | CELLZOME AG (DE) | 2006-05-04 | — | — | WO | disclosed |
| US-20060014945-A1 | N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | US | disclosed |
| WO-2006005486-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
| EP-1370562-A1 | THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | disclosed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | USP2 3304/4885POLB 966/4885ALDH1A1 812/4885 |
| US-20060014945-A1 | N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. | BACE1, APP, BACE2 | USP2 3139/4885POLB 3157/4885ALDH1A1 3005/4885 |
| US-10717726-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | USP2 4672/4885POLB 1548/4885ALDH1A1 133/4885 |
| US-20090118289-A1 | (Biphenyl) Carboxylic Acids and Derivatives Thereof | BACE1, BACE2, APP | USP2 2280/4885POLB 1979/4885ALDH1A1 351/4885 |
| US-20110312945-A1 | CRTH2 MODULATORS | HRH2, HRH1, NR1H2 | USP2 3178/4885POLB 4039/4885ALDH1A1 851/4885 |
| US-20200299280-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | USP2 4672/4885POLB 1548/4885ALDH1A1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.